CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
85.0%+8.1 pts over 5 years
Operating margin
-6.3%+10.8 pts over 5 years
Net margin
-6.4%+2.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.6% | +2.0% | +3.5% | +47.7% | |
| Gross profit | +21.0% | +4.8% | +5.6% | – | |
| Free cash flow | – | -16.7% | -1.7% | -1.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1.3% | -6.8% | -11.9% | |
| Return on assets | -1.0% | -3.3% | -3.7% | |
| Current ratio | 4.43 | 1.95 | 1.01 | |
| Interest coverage | -13.5× | -24.2× | -5.6× | |
| Inventory turnover | 1.2× | 0.9× | 3.3× | |
| Capex to revenue | 0.4% | 0.4% | 0.2% | |
| Diluted shares | 16M | 15M | 15M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cumberland Pharmaceuticals generated $26.43M from operations and spent $4.67M on capital expenditure, dividends and share buybacks. 14% of that went back into the business.
Generated
$26.43M
Used
$4.67M
Capital expenditure$651.31K14%Dividends$00%Share buybacks$4.02M86%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.4%
×Asset turnover0.58×
×Equity multiplier3.19×
=Return on equity, FY2025-11.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.4% | 0.58× | 3.19× | -11.9% |
| FY2024 | -17.1% | 0.48× | 3.00× | -24.7% |
| FY2023 | -15.9% | 0.45× | 2.65× | -19.1% |
| FY2022 | -13.3% | 0.47× | 2.24× | -14.1% |
| FY2021 | -9.7% | 0.40× | 2.01× | -7.8% |
| FY2020 | -8.9% | 0.37× | 2.05× | -6.8% |
| FY2019 | -10.3% | 0.32× | 2.03× | -6.6% |
| FY2018 | -23.7% | 0.29× | 1.72× | -11.6% |
| FY2017 | -19.4% | 0.44× | 1.36× | -11.6% |
| FY2016 | -2.9% | 0.36× | 1.23× | -1.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.84M
- Cash generatingOperating cash flow above zero$4.93M
- Return on assets improvedROA up on the prior year-7.9% → -3.8%
- Earnings backed by cashOperating cash flow above net income$4.93M vs -$2.84M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.15 → 1.01
- No dilutionShare count did not rise14M → 15M
- Gross margin improvedGross margin up on the prior year82.61% → 85.02%
- More efficientAsset turnover rose0.46 → 0.59